Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Balaxi PharmaceuticalsNSE:BALAXI -0.54%63 PS Ratio is 0.48 as of Jul. 14, 2026, which is 75% below its 10-year median of 1.91. GuruFocus rates NSE:BALAXI with a GF Score™ of 63/100 and a GF Value™ of ₹69.51 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 955 Drug Manufacturers companies, Balaxi Pharmaceuticals ranks better than 88.48% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Balaxi Pharmaceuticals's share price is ₹24.04.
Balaxi Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹49.91. Hence, Balaxi Pharmaceuticals's PS Ratio for today is 0.48.
The historical rank and industry rank for Balaxi Pharmaceuticals's PS Ratio or its related term are showing as below:
NSE:BALAXI'
s PS Ratio Range Over the Past 10 Years
Min: 0.32 Med: 1.91 Max: 7200
Current: 0.48
During the past 12 years, Balaxi Pharmaceuticals's highest PS Ratio was 7200.00. The lowest was 0.32. And the median was 1.91.
NSE:BALAXI's PS Ratio is ranked better than 88.48% of 955
companies
in the Drug Manufacturers industry
Industry Median: 2.33
vs NSE:BALAXI: 0.48
During the past 12 years, Balaxi Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 560.80% per year. The lowest was -9.30% per year. And the median was 38.35% per year.
Back to Basics: PS Ratio
Balaxi Pharmaceuticals (NSE:BALAXI) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Balaxi Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Balaxi Pharmaceuticals PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Balaxi Pharmaceuticals's PS Ratio distribution charts can be found below:
* The bar in red indicates where Balaxi Pharmaceuticals's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Balaxi Pharmaceuticals's Share Price of today is ₹24.04. Balaxi Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹49.91.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Balaxi Pharmaceuticals (NSE:BALAXI) has a PS Ratio of 0.48 as of Jul. 14, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Balaxi Pharmaceuticals and its competitors. This is 75% below median its historical median of 1.91. Over the past decade, Balaxi Pharmaceuticals' PS Ratio has ranged from 0.32 to 7,200.00. According to the industry distribution chart, Balaxi Pharmaceuticals ranks #110 out of 955 companies in the Drug Manufacturers industry, placing it in the top 11.5%.
Is Balaxi Pharmaceuticals' PS Ratio too high?
Balaxi Pharmaceuticals' current PS Ratio of 0.48 is 75% below median its 10-year median of 1.91. Over the past 10 years, this metric has ranged from a low of 0.32 to a high of 7,200.00. The Drug Manufacturers industry median PS Ratio is 2.33. Balaxi Pharmaceuticals' value of 0.48 is 79.4% below this industry median. Based on the distribution chart, Balaxi Pharmaceuticals ranks #110 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Balaxi Pharmaceuticals has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Balaxi Pharmaceuticals' PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Balaxi Pharmaceuticals ranks #110 out of 955 companies for PS Ratio. This places Balaxi Pharmaceuticals in the top 12% of its industry — outperforming the majority of peers. The industry median PS Ratio is 2.33. Balaxi Pharmaceuticals' value of 0.48 is 79.4% below this benchmark. Historically, Balaxi Pharmaceuticals' own PS Ratio has ranged from 0.32 to 7,200.00 over the past decade. While the company's 10-year median is 1.91 vs. the industry median of 2.33, Balaxi Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.33, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Balaxi Pharmaceuticals's current PS Ratio of 0.48 is 79.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Balaxi Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Balaxi Pharmaceuticals's current PS Ratio is 0.48, which is 75% below median its own 10-year median of 1.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Balaxi Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Balaxi Pharmaceuticals (NSE:BALAXI) is currently considered Possible Value Trap. The stock's GF Value™ is ₹69.51, compared to a current price of ₹24.04 — trading 65.4% below its estimated fair value. The current PS Ratio is 0.48, which is 75% below median its 10-year median of 1.91 and 79.4% below the Drug Manufacturers industry median of 2.33. Balaxi Pharmaceuticals' overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Balaxi Pharmaceuticals (NSE:BALAXI), the current PS Ratio is 0.48 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Balaxi Pharmaceuticals (NSE:BALAXI) Overvalued in 2026?
Based on GuruFocus' analysis, Balaxi Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹24.04 is trading 65.4% below its estimated GF Value™ of ₹69.51.
GuruFocus considers Balaxi Pharmaceuticals to be Possible Value Trap.
Key valuation signals for NSE:BALAXI:
PS Ratio: 0.48 (75% below median its 10-year median of 1.91)
GF Value™: ₹69.51 vs. price of ₹24.04 (65.4% below fair value)
Industry Position: 79.4% below the Drug Manufacturers median (#110 of 955)
No single metric tells the full story. See the NSE:BALAXI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Balaxi Pharmaceuticals Ltd is an Indian branded IPR-based pharmaceutical company focusing on frontier markets, with a vast and growing portfolio of prescription and OTC drugs, across multiple therapeutic segments. The company operates in single segment Specialized Wholesale. Geographically it earns key revenue from Guatemala.
63GF Score
Get the complete analysis for NSE:BALAXI
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BALAXI has been successfully added to your 
